<DOC>
	<DOC>NCT00779896</DOC>
	<brief_summary>This is an open label, prospective study to evaluate therapeutic potential of Tazarotene 0.1% cream for the treatment of Stage I-IIA CTCL. Patients with Stage I-IIA disease are enrolled into the study. Tazarotene will be used for up to 24 weeks and patients will be followed for up to 12 months.</brief_summary>
	<brief_title>Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Lymphoma, T-Cell, Cutaneous</mesh_term>
	<mesh_term>Nicotinic Acids</mesh_term>
	<mesh_term>Tazarotene</mesh_term>
	<criteria>Patients with Stage IIIA CTCL must be at least 18 years of age with a skin biopsy prior to enrolment confirming the diagnosis of mycosis fungoides. Patients with Stage &gt;IIA CTCL at the time of enrolment Women who are pregnant or planning to get pregnant, or unable/unwilling to use adequate contraception Patients who were treated with topical retinoid therapy in the past 3 months Patients who received any systemic CTCL therapy or systemic corticosteroid therapy within 30 days of the study start date Patients who were treated with systemic isotretinoin or bexarotene within 3 months prior to the study start date, systemic acitretin within 2 years prior to study start date</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>To evaluate therapeutic potential of tazarotene 0.1% cream for the treatment of Stage I-IIA CTCL. Patients with Stage I-IIA disease are enrolled into the study</keyword>
	<keyword>Stage I-IIA disease CTCL</keyword>
</DOC>